MARKET

PLUR

PLUR

PLURILOCK SEC INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
-0.030
-2.75%
Closed 16:00 08/12 EDT
OPEN
1.070
PREV CLOSE
1.090
HIGH
1.100
LOW
1.050
VOLUME
58.78K
TURNOVER
30.82K
52 WEEK HIGH
3.300
52 WEEK LOW
0.9400
MARKET CAP
34.29M
P/E (TTM)
-0.7233
1D
5D
1M
3M
1Y
5Y
Pluri CEO Issues Shareholder Update
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief ...
GlobeNewswire · 07/25 11:00
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
Pluri Inc. logo WHERE TECHNOLOGY COMES TO LIFE As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based p...
GlobeNewswire · 07/25 05:00
Pluristem Therapeutics Changes Name to Pluri as It Seeks Cell-based Products Beyond Medicine
MT Newswires · 07/25 03:17
--Alliance Global Lowers Pluristem Therapeutics' Price Target to $4 From $9.50, Maintains Buy Rating
MT Newswires · 07/20 11:20
HC Wainwright Reiterates On Pluristem After Encouraging Initial Data
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery. 
Benzinga · 07/15 17:32
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Zacks · 07/14 15:15
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary...
Benzinga · 07/13 13:49
Pluristem says Phase 3 trial for muscle injury therapy did not meet key goal
The clinical-stage biotech Pluristem Therapeutics (NASDAQ:PSTI</...
Seekingalpha · 07/13 11:08
More
No Data
Learn about the latest financial forecast of PLUR. Analyze the recent business situations of PLURILOCK SEC INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PLUR stock price target is 3.500 with a high estimate of 4.000 and a low estimate of 3.000.
High4.000
Average3.500
Low3.000
Current 1.060
EPS
Actual
Estimate
-0.37-0.28-0.18-0.09
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 59
Institutional Holdings: 2.20M
% Owned: 6.79%
Shares Outstanding: 32.35M
TypeInstitutionsShares
Increased
9
208.42K
New
7
83.40K
Decreased
9
357.66K
Sold Out
15
1.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.45%
Key Executives
Chairman/Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Independent Director
Doron Birger
Independent Director
Rami Levi
Independent Director
Varda Shalev
Independent Director
Maital Shemesh-Rasmussen
No Data
No Data
About PLUR
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluri Inc stock information, including NASDAQ:PLUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLUR stock methods without spending real money on the virtual paper trading platform.